Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Significant Growth in Short Interest

Aptevo Therapeutics Inc. (NASDAQ:APVO) was the recipient of a significant increase in short interest in April. As of April 30th, there was short interest totalling 268,200 shares, an increase of 84.2% from the April 15th total of 145,600 shares. Currently, 16.8% of the company’s shares are short sold. Based on an average trading volume of 839,900 shares, the short-interest ratio is currently 0.3 days.

Wall Street Analyst Weigh In

Separately, StockNews.com initiated coverage on Aptevo Therapeutics in a report on Thursday, April 18th. They issued a “sell” rating on the stock.

Institutional Trading of Aptevo Therapeutics

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Armistice Capital LLC bought a new position in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 1,235,000 shares of the biotechnology company’s stock, valued at approximately $408,000. Armistice Capital LLC owned approximately 10.72% of Aptevo Therapeutics as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 8.06% of the company’s stock.

Aptevo Therapeutics Stock Performance

Shares of Aptevo Therapeutics stock traded down $0.08 during trading on Monday, reaching $0.81. The stock had a trading volume of 341,340 shares, compared to its average volume of 601,443. The stock has a fifty day moving average price of $2.83 and a two-hundred day moving average price of $6.14. Aptevo Therapeutics has a 52 week low of $0.67 and a 52 week high of $80.96.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.